ATE475649T1 - Pyridincarboxamide als 11-beta-hsd1-inhibitoren - Google Patents

Pyridincarboxamide als 11-beta-hsd1-inhibitoren

Info

Publication number
ATE475649T1
ATE475649T1 AT07824375T AT07824375T ATE475649T1 AT E475649 T1 ATE475649 T1 AT E475649T1 AT 07824375 T AT07824375 T AT 07824375T AT 07824375 T AT07824375 T AT 07824375T AT E475649 T1 ATE475649 T1 AT E475649T1
Authority
AT
Austria
Prior art keywords
beta
hsd1 inhibitors
pyridine carboxamides
carboxamides
pyridine
Prior art date
Application number
AT07824375T
Other languages
English (en)
Inventor
William Mccoull
Martin Packer
James Stewart Scott
Paul Robert Owen Whittamore
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE475649T1 publication Critical patent/ATE475649T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
AT07824375T 2006-11-03 2007-10-31 Pyridincarboxamide als 11-beta-hsd1-inhibitoren ATE475649T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86430306P 2006-11-03 2006-11-03
US86424706P 2006-11-03 2006-11-03
PCT/GB2007/004131 WO2008053194A2 (en) 2006-11-03 2007-10-31 Pyridine carboxamides as 11-beta-hsd1 inhibitors

Publications (1)

Publication Number Publication Date
ATE475649T1 true ATE475649T1 (de) 2010-08-15

Family

ID=39304797

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07824375T ATE475649T1 (de) 2006-11-03 2007-10-31 Pyridincarboxamide als 11-beta-hsd1-inhibitoren

Country Status (30)

Country Link
US (3) US7964618B2 (de)
EP (2) EP2086939B8 (de)
JP (1) JP5165688B2 (de)
KR (1) KR101465275B1 (de)
CN (3) CN101787016B (de)
AR (1) AR063458A1 (de)
AT (1) ATE475649T1 (de)
AU (1) AU2007315955B2 (de)
BR (1) BRPI0717970C1 (de)
CA (1) CA2668006C (de)
CL (1) CL2007003176A1 (de)
CO (1) CO6321130A2 (de)
CY (1) CY1110813T1 (de)
DE (1) DE602007008137D1 (de)
DK (1) DK2086939T3 (de)
ES (2) ES2423206T3 (de)
HR (1) HRP20100522T1 (de)
IL (1) IL198231A0 (de)
MX (1) MX2009004707A (de)
NO (1) NO20091603L (de)
NZ (1) NZ576501A (de)
PE (1) PE20081487A1 (de)
PL (1) PL2086939T3 (de)
PT (1) PT2086939E (de)
RS (1) RS51451B (de)
RU (1) RU2451674C2 (de)
SI (1) SI2086939T1 (de)
TW (1) TW200827346A (de)
UY (1) UY30681A1 (de)
WO (1) WO2008053194A2 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101312951A (zh) 2005-11-21 2008-11-26 盐野义制药株式会社 具有Ⅰ型11β羟基类固醇脱氢酶抑制活性的杂环化合物
TW200827346A (en) * 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
US8314119B2 (en) 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
TW200836719A (en) * 2007-02-12 2008-09-16 Astrazeneca Ab Chemical compounds
US8383622B2 (en) 2007-05-18 2013-02-26 Shionogi & Co., Ltd. Nitrogen-containing heterocyclic derivative having 11β-hydroxysteroid dehydrogenase type I inhibitory activity
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
JP5441705B2 (ja) * 2007-10-15 2014-03-12 武田薬品工業株式会社 アミド化合物およびその用途
WO2009056881A1 (en) * 2007-10-29 2009-05-07 Astrazeneca Ab Chemical compounds 313
CN101969946A (zh) * 2008-02-04 2011-02-09 阿斯利康(瑞典)有限公司 4-[4-(2-金刚烷基氨基甲酰基)-5-叔丁基-吡唑-1-基]苯甲酸的新晶型
BRPI0910734A2 (pt) * 2008-04-22 2015-09-29 Astrazeneca Ab composto, composição farmacêutica, e, processo para preparar um composto ou um sal farmaceuticamente aceitável do mesmo.
US8507493B2 (en) 2009-04-20 2013-08-13 Abbvie Inc. Amide and amidine derivatives and uses thereof
ES2444777T3 (es) 2009-06-12 2014-02-26 Bristol-Myers Squibb Company Compuestos de nicotinamida útiles como moduladores de quinasas
AR078673A1 (es) * 2009-10-20 2011-11-23 Astrazeneca Ab Pirimidinas sustituidas con adamantiliminocarbonilo como inhibidores de 11-b-hsd1 826
WO2011066184A1 (en) * 2009-11-24 2011-06-03 Allergan, Inc. Novel compounds as receptor modulators with therapeutic utility
WO2011068927A2 (en) * 2009-12-04 2011-06-09 Abbott Laboratories 11-β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11B-HSD1) INHIBITORS AND USES THEREOF
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
KR20110123657A (ko) * 2010-05-07 2011-11-15 에스케이케미칼주식회사 피콜린아마이드 및 피리미딘-4-카복사미드 화합물, 이의 제조방법 및 이를 함유하는 약제학적 조성물
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
KR20130108586A (ko) 2010-09-23 2013-10-04 애브비 인코포레이티드 아자아다만탄 유도체의 일수화물
US8471027B2 (en) * 2011-04-06 2013-06-25 Hoffmann-La Roche Inc. Adamantyl compounds
EP2735567B1 (de) * 2011-07-21 2016-10-26 Xuanzhu Pharma Co., Ltd. Heterocyclisch substituierte pyrimidinverbindung
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (de) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridin-4-carbonsäureamidderivate als kinaseinhibitoren
CN102659657B (zh) * 2012-04-24 2014-08-06 徐州医学院 一种蛋白酶抑制剂pf429242的合成方法
PE20142448A1 (es) 2012-06-20 2015-01-28 Hoffmann La Roche Compuestos de n-alquiltriazol como antagonistas de lpar
IN2014DN09347A (de) 2012-06-20 2015-07-17 Hoffmann La Roche
EP3821892A1 (de) 2019-11-12 2021-05-19 University of Leeds (s)-2-(1-(5-(cyclohexylcarbamoyl)-6-(propylthio)pyridin-2-yl)piperidin-3-yl)essigsäure zur verwendung bei der wundheilung
GB202216324D0 (en) * 2022-11-02 2022-12-14 Cerevance Ltd Novel compounds
GB202408335D0 (en) 2024-06-11 2024-07-24 Astrazeneca Ab Therapies for wound treatment

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR66581B (de) * 1978-02-21 1981-03-27 Delalande Sa
CA1307786C (en) 1984-12-14 1992-09-22 Keiichi Yokoyama Quinazoline derivatives and antihypertensive preparations containing same as effective components
TR200200701T2 (tr) 1999-09-16 2002-06-21 Tanabe Seiyaku Co., Ltd. Altı-elementli aromatik nitrojenli halka bileşimleri.
FR2803592A1 (fr) * 2000-01-06 2001-07-13 Aventis Cropscience Sa Nouveaux derives de l'acide 3-hydroxypicolinique, leur procede de preparation et compositions fongicides les contenant.
US7273868B2 (en) * 2000-04-28 2007-09-25 Tanabe Seiyaku Co., Ltd. Pyrazine derivatives
US6777446B2 (en) 2000-09-05 2004-08-17 Tularik, Inc. FXR modulators
NZ526003A (en) 2000-10-20 2005-09-30 Biocryst Pharm Inc Biaryl compounds as serine protease inhibitors
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
AU2003217046A1 (en) 2002-04-05 2003-10-27 The University Of Edinburgh Pharmaceutical compositions comprising a 11-beta hydroxysteroid dehydrogenase inhibitor and a diuretic agent
WO2004039795A2 (en) * 2002-10-29 2004-05-13 Fujisawa Pharmaceutical Co., Ltd. Amide compounds for the treatment of hyperlipidemia
TW200503994A (en) * 2003-01-24 2005-02-01 Novartis Ag Organic compounds
SE0300458D0 (sv) * 2003-02-19 2003-02-19 Astrazeneca Ab Novel compounds
SE0300457D0 (sv) * 2003-02-19 2003-02-19 Astrazeneca Ab Novel compounds
MXPA05009059A (es) 2003-02-26 2005-10-19 Banyu Pharma Co Ltd Derivados de heteroarilcarbamoilbenceno.
EP1615698B1 (de) 2003-04-11 2010-09-29 High Point Pharmaceuticals, LLC Neue amide derivate und deren pharmazeutische verwendungen
CA2534221A1 (en) 2003-08-07 2005-02-24 Merck & Co., Inc. Pyrazole carboxamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
US7749999B2 (en) 2003-09-11 2010-07-06 Itherx Pharmaceuticals, Inc. Alpha-ketoamides and derivatives thereof
GB0327761D0 (en) 2003-11-29 2003-12-31 Astrazeneca Ab Compounds
KR20060101772A (ko) 2003-12-19 2006-09-26 화이자 인코포레이티드 당뇨병 및 비만을 치료하기 위한,11-베타-하이드록시스테로이드 데하이드로게나제 유형1(11-베타-ｈｓｄ-1)의 저해제로서의벤젠설폰일아미노-피리딘-2-일 유도체 및 관련 화합물
DE602005009500D1 (de) 2004-02-24 2008-10-16 Glaxo Group Ltd Pyridinderivate und deren verwendung als modulatoren des cb2-rezeptors
MXPA06011414A (es) * 2004-03-31 2007-04-20 Johnson & Johnson Compuestos heterociclicos sin imidazol como ligandos del receptor de h3 histamina.
MXPA06012831A (es) 2004-05-06 2007-01-26 Pfizer Nuevos compuestos de derivados de morfolina y prolina.
TW200600086A (en) 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
MXPA06014892A (es) 2004-06-28 2007-02-28 Hoffmann La Roche Derivados de pirimidina como inhibidores de la enzima 11beta-hidroxiesteroide-deshidrogenasa de tipo 1 (11beta-hsd1).
CA2585735A1 (en) 2004-11-02 2006-05-11 Pfizer Inc. Novel compounds of substituted and unsubstituted adamantyl amides
JP2008519034A (ja) 2004-11-03 2008-06-05 バーテックス ファーマシューティカルズ インコーポレイテッド イオンチャネル調節剤としてのピリミジン誘導体および使用方法
EP1846363B1 (de) 2005-01-05 2012-04-25 Abbott Laboratories Adamantyl-derivate als inhibitoren des 11-beta-hydroxysteroid-dehydrogenase-1-enzyms
WO2006106052A1 (en) * 2005-04-05 2006-10-12 F. Hoffmann-La Roche Ag Pyrazoles
MX2007012213A (es) 2005-04-06 2007-12-10 Hoffmann La Roche Derivados de piridin-3-carboxamida como agonistas inversos de canabinoides.
WO2006106423A2 (en) 2005-04-07 2006-10-12 Pfizer Inc. Amino sulfonyl derivatives as inhibitors of human 11-.beta.-hydrosysteroid dehydrogenase
EP2527337A1 (de) 2005-04-14 2012-11-28 Bristol-Myers Squibb Company Hemmer des 11-Beta-Hydroxysteroid-Dehydrogenase-1-Enzyms
WO2006125958A1 (en) 2005-05-24 2006-11-30 Astrazeneca Ab 2-phenyl substituted imidazol [4 , 5b] pyridine/ pyrazine and purine derivatives as glucokinase modulators
WO2006132197A1 (ja) 2005-06-07 2006-12-14 Shionogi & Co., Ltd. I型11βヒドロキシステロイド脱水素酵素阻害活性を有するヘテロ環化合物
EP1889842A4 (de) 2005-06-08 2009-07-29 Japan Tobacco Inc Heterozyklische verbindung
ES2334518T3 (es) 2005-06-16 2010-03-11 Pfizer, Inc. Derivados de n-(piridin-2-il)-sulfonamida.
NZ575512A (en) 2005-07-09 2009-11-27 Astrazeneca Ab Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
EP1915367A1 (de) 2005-08-09 2008-04-30 AstraZeneca AB Heteroarylcarbamoylbenzolderivate zur behandlung von diabetes
JP2009513711A (ja) 2005-11-01 2009-04-02 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ グルコキナーゼのアロステリックモジュレーターとしての置換ピロロン
WO2007052843A1 (ja) 2005-11-04 2007-05-10 Takeda Pharmaceutical Company Limited 複素環アミド化合物およびその用途
CN101312951A (zh) 2005-11-21 2008-11-26 盐野义制药株式会社 具有Ⅰ型11β羟基类固醇脱氢酶抑制活性的杂环化合物
EA200870216A1 (ru) 2006-01-31 2009-02-27 Инсайт Корпорейшн Амидо соединения и их применение в качестве лекарственных средств
KR101077366B1 (ko) 2006-03-22 2011-10-26 에프. 호프만-라 로슈 아게 11-베타-ｈｓｄ-1로서의 피라졸
CN101448782A (zh) 2006-04-07 2009-06-03 高点制药有限责任公司 对1型11β-羟基甾体脱氢酶具有活性的化合物
WO2007125049A1 (en) 2006-04-27 2007-11-08 Solvay Pharmaceuticals Gmbh Use of cbx cannabinoid receptor modulators as potassium channel modulators
US20100022589A1 (en) * 2006-07-27 2010-01-28 Mccoull William Pyridine-3-carboxamide compounds and their use for inhibiting 11-beta-hydroxysteroid dehydrogenase
TW200827346A (en) * 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
TW200836719A (en) * 2007-02-12 2008-09-16 Astrazeneca Ab Chemical compounds
US8383622B2 (en) 2007-05-18 2013-02-26 Shionogi & Co., Ltd. Nitrogen-containing heterocyclic derivative having 11β-hydroxysteroid dehydrogenase type I inhibitory activity
EP2178845B1 (de) 2007-07-17 2013-06-19 F. Hoffmann-La Roche AG Inhibitoren von 11b-hydroxysteroiddehydrogenase
JP2011502978A (ja) 2007-11-06 2011-01-27 アストラゼネカ アクチボラグ ４−［４−（２−アダマンチルカルバモイル）−５−ｔｅｒｔ−ブチル−ピラゾル−１−イル］安息香酸−４６５
CN101969946A (zh) * 2008-02-04 2011-02-09 阿斯利康(瑞典)有限公司 4-[4-(2-金刚烷基氨基甲酰基)-5-叔丁基-吡唑-1-基]苯甲酸的新晶型
BRPI0910734A2 (pt) * 2008-04-22 2015-09-29 Astrazeneca Ab composto, composição farmacêutica, e, processo para preparar um composto ou um sal farmaceuticamente aceitável do mesmo.
CN102300851A (zh) 2009-01-30 2011-12-28 阿斯利康(瑞典)有限公司 制备含羧基的吡唑酰氨基化合物597的新方法
AR078673A1 (es) * 2009-10-20 2011-11-23 Astrazeneca Ab Pirimidinas sustituidas con adamantiliminocarbonilo como inhibidores de 11-b-hsd1 826

Also Published As

Publication number Publication date
EP2086939B1 (de) 2010-07-28
PL2086939T3 (pl) 2011-09-30
SI2086939T1 (sl) 2010-10-29
PE20081487A1 (es) 2009-01-11
AU2007315955B2 (en) 2011-04-14
EP2086939A2 (de) 2009-08-12
EP2233480A1 (de) 2010-09-29
TW200827346A (en) 2008-07-01
AR063458A1 (es) 2009-01-28
US8673938B2 (en) 2014-03-18
US20090312372A1 (en) 2009-12-17
ES2423206T3 (es) 2013-09-18
JP5165688B2 (ja) 2013-03-21
DK2086939T3 (da) 2010-10-11
CN101573336A (zh) 2009-11-04
NO20091603L (no) 2009-05-28
EP2233480B1 (de) 2013-05-29
BRPI0717970B8 (pt) 2020-12-01
UY30681A1 (es) 2008-07-03
CN102603711A (zh) 2012-07-25
US20090306075A1 (en) 2009-12-10
WO2008053194A2 (en) 2008-05-08
BRPI0717970A2 (pt) 2013-11-05
EP2086939B8 (de) 2011-06-22
JP2010508338A (ja) 2010-03-18
MX2009004707A (es) 2009-05-15
ES2347491T3 (es) 2010-10-29
PT2086939E (pt) 2010-09-17
US7964618B2 (en) 2011-06-21
CL2007003176A1 (es) 2008-07-25
RU2009115830A (ru) 2010-12-10
DE602007008137D1 (en) 2010-09-09
IL198231A0 (en) 2009-12-24
HK1135090A1 (en) 2010-05-28
BRPI0717970B1 (pt) 2019-10-22
KR20090075865A (ko) 2009-07-09
AU2007315955A1 (en) 2008-05-08
CN101787016A (zh) 2010-07-28
CY1110813T1 (el) 2015-06-10
RS51451B (sr) 2011-04-30
BRPI0717970C1 (pt) 2021-05-25
CN101573336B (zh) 2012-03-21
HRP20100522T1 (hr) 2010-11-30
CA2668006C (en) 2016-05-24
WO2008053194A3 (en) 2008-10-02
US20080269288A1 (en) 2008-10-30
NZ576501A (en) 2011-03-31
CO6321130A2 (es) 2011-09-20
CN101787016B (zh) 2013-08-28
KR101465275B1 (ko) 2014-11-27
RU2451674C2 (ru) 2012-05-27
CA2668006A1 (en) 2008-05-08

Similar Documents

Publication Publication Date Title
ATE475649T1 (de) Pyridincarboxamide als 11-beta-hsd1-inhibitoren
FIC20250030I1 (fi) Lekanemabi
FIC20220006I1 (fi) Tafasitamabi
DK2041138T3 (da) Pyrroltriazinkinase-inhibitorer
CY2017016I2 (el) Αναστολεις πρωτεασωματος
DK2024375T3 (da) Cyclopropyl-kondenserede indolobenzazepin-HCV-NS5B-hæmmere
ATE510825T1 (de) Acylaminopyrazole als fgfr-inhibitoren
DK2089364T3 (da) Pyridinonforbindelser
CR10831A (es) INHIBIDORES ESPIRO CETONA DE ACETIL-CoA CARBOXILASA
EP2087096A4 (de) Modifizierte cyanobakterien
DE602007012130D1 (de) Modifizierte flavin-adenin-dinucleotid-abhängige glucose-dehydrogenase
ATE467623T1 (de) Diazepan-acetamidderivate als selektive 11-hsd1- hemmer
CR10478A (es) Amino-piperidine derivatives as cetp inhibitors
EP2033216A4 (de) Elektroadhäsion
DE602006004717D1 (de) Kapselperforationsmodul
ATE543816T1 (de) Azacycloalkanderivate als inhibitoren von stearoyl-coenzym-a-delta-9-desaturase
BRPI0717939A2 (pt) Aminometil-4-imidazóis
DE602007009461D1 (de) Tonwiedergabegerät
DK2066662T3 (da) Serinhydrolaseinhibitorer
ATE495153T1 (de) Arylsulfonylpyrrolidine als 5-ht6-inhibitoren
EP2054074A4 (de) Modifiziertes erythropoietin
ITPD20060387A1 (it) Espositore
EP1977052A4 (de) Urinal mit anti-rückspritz-funktion
FI20075320A0 (fi) Uusia käyttökelpoisia inhibiittoreita
DK1913850T3 (da) Sengetøj

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2086939

Country of ref document: EP